COVID-19

[Autophagy] Researchers identified ORF3a as an inducer of autophagy and revealed that ORF3a localized to the ER and induced RETREG1/FAM134B-related reticulophagy through the HMGB1-BECN1 pathway.

[Nature News] Two years into the pandemic, the COVID-19 drugs pipeline is primed to pump out novel treatments — and fresh uses for familiar therapies.

[Nature Medicine] Investigators reported the results of the open-label, non-randomized part B of a Phase II trial in which they evaluated the safety and immunogenicity of a booster injection of 50 µg of the COVID-19 vaccine mRNA-1273 in 344 adult participants immunized 6–8 months earlier with a primary series of two doses of 50 µg or 100 µg of mRNA-1273.

[Statera Biopharma, Inc.] Statera Biopharma, Inc. announced submission to the FDA of its pilot study protocol for STAT-205 treatment of post-acute COVID-19.

[Journal of Reproductive Immunology] Investigators hypothesized that decidual leukocytes were altered by maternal SARS-CoV-2 infection in pregnancy and that this decidual immune response was shaped by the timing of infection during gestation.

[Journal of infectious Diseases] The authors studied urine and blood nucleocapsid antigen using a highly sensitive immunoassay in 82 patients with a SARS-CoV-2 infection proven by PCR.